Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band



Status:Completed
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 60
Updated:4/21/2016
Start Date:August 2006
End Date:January 2015

Use our guide to learn which trials are right for you!

A Post Implantation/Post Market Evaluation of Safety and Quality of Life in Subjects Implanted With the Swedish Adjustable Gastric Band (SAGB) During Protocol CI-02-0006

The purpose of the study is to evaluate the long term safety of the Swedish Adjustable
Gastric Band (SAGB) in subjects with an SAGB in place. Specifically it is designed to
determine the re-operation rate (band revision, band replacement and explants resulting from
serious adverse device-related event {SADE}) of gastric banding at 4 and 5 year post
implant.

NCT00543140 (CI-06-0001) is the 2 year Safety and QOL subject follow-up study to NCT00166205
(CI-02-0006), completed on November 10, 2008. As a condition of approval, the FDA required
additional subjects with long-term safety data. These subjects enrolled under protocol
CI-07-0006 (NCT00813462)-5 Year Post-Approval Study With the REALIZE (TM) Adjustable Gastric
Band. Protocol CI-06-0001 was amended to combine these study subjects with study subjects
from CI-07-0006. NCT00543140 (CI-06-0001) will not be completed (analysis of results) until
the additional subjects in NCT00813462 (CI-07-0006) complete this study since the original
intent was to pool the data together from the above two studies to obtain the appropriate
sample size for estimation of the re-operation rate at 4 and 5 years post implantation.

CI-06-0001 Inclusion Criteria:

Subjects eligible to participate in this study must fulfill all of the following criteria:

1. Able to comprehend, follow and give signed informed consent;

2. Consented to, and participated in EES Protocol CI-02-0006 titled "A Single-Arm,
Multi-Center Study of the Safety and Effectiveness of The Swedish Adjustable Gastric
Band (SAGB) in the Treatment of Morbid Obesity";

3. Currently have an SAGB implant in place;

4. Able to commit to long-term follow-up; up to 5 years after SAGB implantation,
including band adjustment visits; and

5. Living within the contiguous U.S.

CI-07-0006 Inclusion Criteria:

Subjects eligible to participate in this study must fulfill all of the following criteria:

1. Able to comprehend, follow and give informed consent;

2. 18 to 60 years of age (inclusive);

3. Body Mass Index (BMI) of > 40 kg/m2 and £ 55 kg/m2, or BMI ³ 35 kg/m2 and < 40 kg/m2
with one or more co-morbid conditions.

4. Candidate for surgical weight loss intervention in accordance with the Instructions
For Use (i.e., meets acceptable health criteria for major surgery).

CI-06-0001 Exclusion Criteria:

Subjects with the following are not eligible to participate in this clinical trial and
must not be enrolled in this study:

a. Consented to, and participated in EES Protocol CI-02-0006 titled "A aSingle-Arm,
Multi-Center Study of the Safety and Effectiveness of The Swedish Adjustable Gastric Band
(SAGB) in the Treatment of Morbid Obesity"; and have had the SAGB explanted.

CI-07-0006 Exclusion Criteria:

1. Women who are currently pregnant.

2. Previous malabsorptive or restrictive procedures performed for the treatment of
morbid obesity.

3. Documented history of drug and/or alcohol abuse within 2 years of the Screening Visit
(1a).

4. Presence of any of the following medical conditions;

1. Inflammatory diseases of the gastrointestinal tract, including severe
intractable esophagitis, gastric ulceration or duodenal ulceration, or specific
inflammation such as Crohn's disease;

2. Severe cardiopulmonary disease or other serious organic disease;

3. Upper gastrointestinal bleeding conditions such as esophageal or gastric varices
or intestinal telangiectases;

4. Portal hypertension;

5. Anomalies of the gastrointestinal tract such as atresia or stenosis;

6. Cirrhosis of the liver;

7. Chronic pancreatitis;

8. Patients on chronic, long-term steroid treatment or steroids within 15 days of
surgery;

9. Unable or unwilling to comply with dietary restrictions required by this
procedure;

10. Known allergy to materials contained within the band or its injection port
(silicone elastomer containing 10% BaSO4, polyetheretherketone (PEEK), and
cobalt chromium)

5. Presence of terminal illness with life expectancy of £ 5 years.

6. Inability to refrain from use of anticoagulants or aspirin within 15 days prior to
surgery.

7. Acute or chronic infection (localized or systemic).

8. Participation in another clinical trial within 8 weeks of the Screening Visit (1a)
and for the duration of this trial.

9. Any medical condition or finding for which the Investigator utilizes their medical
discretion to determine the subject should be excluded due to inability to understand
or follow study procedures.
We found this trial at
8
sites
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1111 Amsterdam Ave
New York, New York 10025
(212) 523-4000
St Luke's - Roosevelt Hospital Center With 523 beds, Mount Sinai St. Luke's serves as...
?
mi
from
New York, NY
Click here to add this to my saved trials
2950 Cleveland Clinic Blvd.
Weston, Florida 33331
866.293.7866
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
?
mi
from
Weston, FL
Click here to add this to my saved trials
?
mi
from
Dalton, GA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
St. Augustine, Florida 32086
?
mi
from
St. Augustine, FL
Click here to add this to my saved trials